EC approves Merck and Pfizer’s renal cell carcinoma treatment
The European Commission (EC) has approved Merck and Pfizer’s Bavencio (avelumab), in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Both companies say that the approval made as a result of positive interim results from the Phase III JAVELIN Renal 101 study, which found that the combination